On this page
Good Sense Naproxen Sodium
Naproxen Sodium · Tablet, Film Coated
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Anti-Inflammatory Agents | EPC | All 251 members |
| Cyclooxygenase Inhibitors [MoA] | MoA | All 251 members |
| Histamine H1 Receptor Antagonists [MoA] | MoA | All 136 members |
| Histamine-1 Receptor Antagonist [EPC] | EPC | All 134 members |
| Non-Steroidal [CS] | CS | All 251 members |
| Nonsteroidal Anti-inflammatory Drug [EPC] | EPC | All 251 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 074661-001 | NAPROXEN SODIUM | TABLET | NAPROXEN SODIUM | Over-the-counter | — |
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 40 | Labeling | Approved | November 12, 2014 | — |
| Supplement | 62 | Labeling | Approved | October 25, 2014 | Standard |
| Supplement | 58 | Labeling | Approved | October 25, 2014 | Standard |
| Supplement | 54 | Labeling | Approved | October 25, 2014 | Standard |
| Supplement | 44 | Labeling | Approved | January 19, 2012 | — |
| Supplement | 43 | Labeling | Approved | September 7, 2010 | — |
| Supplement | 28 | Labeling | Approved | December 19, 2006 | — |
| Supplement | 27 | Labeling | Approved | March 13, 2006 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | November 20, 2002 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | November 20, 2002 | — |
| Supplement | 8 | Labeling | Approved | December 10, 2001 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | August 25, 1999 | — |
| Supplement | 4 | Labeling | Approved | February 19, 1999 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | August 28, 1998 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | August 11, 1997 | — |
| Original application | 1 | Approved | January 13, 1997 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260511). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingUses • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold • temporarily reduces fever
Purpose
openFDA Drug LabelingPurposes Nighttime sleep-aid Pain reliever
Dosage and Administration
openFDA Drug LabelingDirections • do not take more than directed • the smallest effective dose should be used • drink a full glass of water with each dose Adults and children 12 years and older: • take 1 tablet every 8 to 12 hours while symptoms last • for the first dose you may take 2 tablets within the first hour • do not exceed 2 tablets in any 8- to 12-hour period • do not exceed 3 tablets in a 24-hour period Children under 12 years: • ask a doctor
Warnings
openFDA Drug LabelingWarnings Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include: • hives • facial swelling • asthma (wheezing) • shock • skin reddening • rash • blisters If an allergic reaction occurs, stop use and seek medical help right away. Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you: • are age 60 or older • have had stomach ulcers or bleeding problems • take a blood thinning (anticoagulant) or steroid drug • take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) • have 3 or more alcoholic drinks every day while using this product • take more or for a longer time than directed Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed. Do not use • if you have ever had an allergic reaction to any other pain reliever/fever reducer • unless you have time for a full night’s sleep • in children under 12 years of age • right before or after heart surgery • with any other product containing diphenhydramine, even one used on skin • if you have sleeplessness without pain Ask a doctor before use if • stomach bleeding warning applies to you • you have problems or serious side effects from taking pain relievers or fever reducers • you have a history of stomach problems, such as heartburn • you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke • you are taking a diuretic • you have a breathing problem such as emphysema or chronic bronchitis • you have glaucoma • you have trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are • taking sedatives or tranquilizers, or any other sleep-aid • under a doctor’s care for any serious condition • taking aspirin for heart attack or stroke, because naproxen may decrease this benefit of aspirin • taking any other antihistamines • taking any other drug When using this product • drowsiness will occur • avoid alcoholic drinks • do not drive a motor vehicle or operate machinery • take with food or milk if stomach upset occurs Stop use and ask a doctor if • you experience any of the following signs of stomach bleeding: • feel faint • vomit blood • have bloody or black stools • have stomach pain that does not get better • you have symptoms of heart problems or stroke: • chest pain • trouble breathing • weakness in one part or side of body • slurred speech • leg swelling • pain gets worse or lasts more than 10 days • sleeplessness persists continuously for more than 2 weeks. Insomnia may be a symptom of a serious underlying medical illness. • redness or swelling is present in the painful area • any new symptoms appear • you have difficulty swallowing • it feels like the pill is stuck in your throat If pregnant or breast feeding ask a health professional before use. It is especially important not to use naproxen sodium at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Do Not Use
openFDA Drug LabelingDo not use • if you have ever had an allergic reaction to any other pain reliever/fever reducer • unless you have time for a full night’s sleep • in children under 12 years of age • right before or after heart surgery • with any other product containing diphenhydramine, even one used on skin • if you have sleeplessness without pain
Ask a Doctor
openFDA Drug LabelingAsk a doctor before use if • stomach bleeding warning applies to you • you have problems or serious side effects from taking pain relievers or fever reducers • you have a history of stomach problems, such as heartburn • you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke • you are taking a diuretic • you have a breathing problem such as emphysema or chronic bronchitis • you have glaucoma • you have trouble urinating due to an enlarged prostate gland
Stop Use
openFDA Drug LabelingStop use and ask a doctor if • you experience any of the following signs of stomach bleeding: • feel faint • vomit blood • have bloody or black stools • have stomach pain that does not get better • you have symptoms of heart problems or stroke: • chest pain • trouble breathing • weakness in one part or side of body • slurred speech • leg swelling • pain gets worse or lasts more than 10 days • sleeplessness persists continuously for more than 2 weeks. Insomnia may be a symptom of a serious underlying medical illness. • redness or swelling is present in the painful area • any new symptoms appear • you have difficulty swallowing • it feels like the pill is stuck in your throat
Active Ingredient
openFDA Drug LabelingActive ingredients (in each caplet) Diphenhydramine hydrochloride 25 mg Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Naproxen Sodium Tablets 220mg - Blue (Light Blue), Oval, Imprint "L368". NDC 71335-2584-1: 20 Tablets in a BOTTLE NDC 71335-2584-2: 30 Tablets in a BOTTLE NDC 71335-2584-3: 40 Tablets in a BOTTLE NDC 71335-2584-4: 50 Tablets in a BOTTLE NDC 71335-2584-5: 60 Tablets in a BOTTLE NDC 71335-2584-6: 14 Tablets in a BOTTLE NDC 71335-2584-7: 100 Tablets in a BOTTLE NDC 71335-2584-8: 90 Tablets in a BOTTLE NDC 71335-2584-9: 24 Tablets in a BOTTLE Store at 20-25°C (68-77°F). Avoid high humidity and excessive heat above 40°C (104°F). Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: DIPHENHYDRAMINE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 71335-2584-1 | 71335-2584 | Bryant Ranch Prepack | 20 TABLET, FILM COATED in 1 BOTTLE (71335-2584-1) | April 3, 2025 |
| 71335-2584-2 | 71335-2584 | Bryant Ranch Prepack | 30 TABLET, FILM COATED in 1 BOTTLE (71335-2584-2) | April 3, 2025 |
| 71335-2584-3 | 71335-2584 | Bryant Ranch Prepack | 40 TABLET, FILM COATED in 1 BOTTLE (71335-2584-3) | April 3, 2025 |
| 71335-2584-4 | 71335-2584 | Bryant Ranch Prepack | 50 TABLET, FILM COATED in 1 BOTTLE (71335-2584-4) | April 3, 2025 |
| 71335-2584-5 | 71335-2584 | Bryant Ranch Prepack | 60 TABLET, FILM COATED in 1 BOTTLE (71335-2584-5) | April 3, 2025 |
| 71335-2584-6 | 71335-2584 | Bryant Ranch Prepack | 14 TABLET, FILM COATED in 1 BOTTLE (71335-2584-6) | April 3, 2025 |
| 71335-2584-7 | 71335-2584 | Bryant Ranch Prepack | 100 TABLET, FILM COATED in 1 BOTTLE (71335-2584-7) | April 3, 2025 |
| 71335-2584-8 | 71335-2584 | Bryant Ranch Prepack | 90 TABLET, FILM COATED in 1 BOTTLE (71335-2584-8) | April 3, 2025 |
| 71335-2584-9 | 71335-2584 | Bryant Ranch Prepack | 24 TABLET, FILM COATED in 1 BOTTLE (71335-2584-9) | April 3, 2025 |
| 0113-0901-62 | 0113-0901 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-0901-62) / 24 TABLET, FILM COATED in 1 BOTTLE | April 23, 2014 |
| 0113-0901-71 | 0113-0901 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-0901-71) / 50 TABLET, FILM COATED in 1 BOTTLE | April 23, 2014 |
| 0113-0901-75 | 0113-0901 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-0901-75) / 90 TABLET, FILM COATED in 1 BOTTLE | December 8, 2021 |
| 0113-1412-71 | 0113-1412 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-1412-71) / 50 TABLET, FILM COATED in 1 BOTTLE | November 9, 2021 |
| 0113-4368-62 | 0113-4368 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-4368-62) / 24 TABLET, FILM COATED in 1 BOTTLE | March 31, 2014 |
| 0113-4368-71 | 0113-4368 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-4368-71) / 50 TABLET, FILM COATED in 1 BOTTLE | March 31, 2014 |
| 0113-4368-75 | 0113-4368 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-4368-75) / 90 TABLET, FILM COATED in 1 BOTTLE | December 8, 2021 |
| 0113-4368-79 | 0113-4368 | L. Perrigo Company | 400 TABLET, FILM COATED in 1 BOTTLE (0113-4368-79) | June 19, 2018 |
| 0113-4368-82 | 0113-4368 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-4368-82) / 200 TABLET, FILM COATED in 1 BOTTLE (0113-4368-00) | April 2, 2026 |
| 0113-8264-06 | 0113-8264 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-8264-06) / 160 TABLET, FILM COATED in 1 BOTTLE (0113-8264-00) | February 26, 2026 |
| 0113-8264-60 | 0113-8264 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-8264-60) / 20 TABLET, FILM COATED in 1 BOTTLE | December 28, 2018 |
| 0113-8264-71 | 0113-8264 | L. Perrigo Company | 1 BOTTLE in 1 CARTON (0113-8264-71) / 50 TABLET, FILM COATED in 1 BOTTLE | March 14, 2022 |
| 68788-8443-2 | 68788-8443 | Preferred Pharmaceuticals Inc. | 20 TABLET, FILM COATED in 1 BOTTLE (68788-8443-2) | May 10, 2023 |
| 68788-8443-3 | 68788-8443 | Preferred Pharmaceuticals Inc. | 30 TABLET, FILM COATED in 1 BOTTLE (68788-8443-3) | May 10, 2023 |
| 68788-8443-4 | 68788-8443 | Preferred Pharmaceuticals Inc. | 40 TABLET, FILM COATED in 1 BOTTLE (68788-8443-4) | May 10, 2023 |
| 68788-8443-6 | 68788-8443 | Preferred Pharmaceuticals Inc. | 60 TABLET, FILM COATED in 1 BOTTLE (68788-8443-6) | May 10, 2023 |
| 63187-794-20 | 63187-794 | Proficient Rx LP | 20 TABLET, FILM COATED in 1 BOTTLE (63187-794-20) | December 1, 2016 |
| 63187-794-30 | 63187-794 | Proficient Rx LP | 30 TABLET, FILM COATED in 1 BOTTLE (63187-794-30) | December 1, 2016 |
| 63187-794-60 | 63187-794 | Proficient Rx LP | 60 TABLET, FILM COATED in 1 BOTTLE (63187-794-60) | December 1, 2016 |
| 71335-2584 | 71335-2584 | Bryant Ranch Prepack | — | March 31, 2014 |
| 0113-0901 | 0113-0901 | L. Perrigo Company | — | April 23, 2014 |
| 0113-1412 | 0113-1412 | L. Perrigo Company | — | November 9, 2021 |
| 0113-4368 | 0113-4368 | L. Perrigo Company | — | March 31, 2014 |
| 0113-8264 | 0113-8264 | L. Perrigo Company | — | December 28, 2018 |
| 68788-8443 | 68788-8443 | Preferred Pharmaceuticals Inc. | — | May 10, 2023 |
| 63187-794 | 63187-794 | Proficient Rx LP | — | March 31, 2014 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.